Variable expressivity and novel PTEN mutations in Cowden syndrome

Renato Assis Machado, DDS, MDS, PhD, a Lívia Maris Ribeiro Paranaiba, DDS, MDS, PhD, b Luciane Martins, BSc, PhD, c Mário Rodrigues Melo-Filho, DDS, MDS, PhD, d Thays Teixeira de Souza, DDS, MDS, e Bruna Lavinas Sayed Picciani, DDS, MDS, PhD, e Geraldo Oliveira Silva-Junior, DDS, MSc, PhD, e Marliana Heffer Cantonisano, DDS, MDS, PhD, e Breno Amaral Rocha, DDS, f Fábio Ramoa Pires, DDS, MDS, PhD, e and Ricardo D. Coletta, DDS, MDS, PhD a

Cowden syndrome (CS) is a phosphatase and tensin homolog gene (PTEN)—associated condition characterized by multiple mucocutaneous hamartomas and an increased risk of malignancies. We reported an isolated case and another of several individuals in one family affected by CS. The isolated case showed typical features, including fibrocystic breast disease, benign thyroid nodules, and multiple papillomatous lesions in the face and oral cavity, and the cause was a novel nonsense mutation—guanine (G) to thymine (T) transition at position 940 (c.940 G>T)—in PTEN. In the family, the proband showed erythema nodosum, duodenal ulcer, intestinal polyps, cervical lipoma, renal cysts, and glaucoma, whereas multiple members of her family were found to have intestinal polyps, and a sister had been diagnosed with breast cancer at early age. An intronic mutation—T

Cowden syndrome (CS; OMIM #158350) is an autosomal dominant condition with a prevalence of approximately 1:200,000.1 It is characterized by multiple hamartomatous lesions, especially in skin and mucous membranes, and an increased risk of benign and malignant tumors.2 Its clinical expression is highly variable.3 A few years after the first report, mutations in the phosphatase and tensin homolog gene (PTEN), which is localized in 10q23.2, were associated with CS.4 Mutations in PTEN have been also described in Bannayan-Riley-Ruvalcaba syndrome, Lhermitte-Duclos disease, and possibly Proteus syndrome.5 Although those disorders show distinctive clinical features, they are grouped together under the spectrum of PTEN-hamartoma tumor syndrome.6

Currently, it is accepted that most patients with typical features of CS have PTEN mutations, and the remainder remains unexplained, suggesting a possible genetic heterogeneity for this disease.2,6 Here, we report one isolated case of CS (de novo mutation) and one family with several members affected by CS displaying PTEN mutations and variable clinical expressivity. Molecular analysis identified a heterozygous nonsense mutation (c.940 G>T) in exon 8 of PTEN in the isolated case; in the family, affected individuals demonstrated a homozygous c.1026+32 T>G in PTEN, which is predicted to create a new splicing site.

MATERIALS AND METHODS
Written informed consent was obtained in compliance with the tenets of the Declaration of Helsinki—Ethical Principles for Medical Research Involving Human Subjects.

Mutational analysis of candidate gene
Genomic DNA was isolated from the buccal mucosa cells by using a salting-out protocol.7 PTEN genomic variants were detected by DNA direct sequencing in family members enrolled in the study. PTEN was amplified by polymerase chain reaction (PCR) by using primers designed to investigate all exons and splicing junctions (Supplementary Table 1). Direct DNA sequencing of PCR products was performed by using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) and migrated
on capillary 3500 Genetic Analyzer (Applied Biosystems, Foster City, CA).

**Residue conservation analysis**

Multiple-species amino acid sequence alignment of the PTEN protein was performed by using Clustal Omega (European Bioinformatics Institute, EMBL-EBI; http://www.ebi.ac.uk/Tools/msa/clustalo/). Sequence logo for PTEN sequences was carried out by using WebLogo analysis. The following PTEN sequences were used: human (NP_000305.3), monkey (NP_001247894.1), chimpanzee (XP_016774311.1), mouse (NP_032986.1), rat (NP_113794.1), dog (NP_001003192.1), cat (XP_003993913.1), pig (NP_001137168.1), cattle (XP_002698416.1), chicken (XP_015134187.1), frog (NP_001116943.1), and zebrafish (NP_001001822).

**PTEN structure and contact analysis**

Three-dimensional (3-D) models for the native and mutant forms based in the isoform A of PTEN (UniProt: F6 KD01) and in the previously determined mutant (p.E314*) forms were built by using the SWISS-MODEL software. The superimposition of the predicted 3-D structure of p.E314* mutant PTEN with wild-type PTEN structure, alignment, visualization, and analysis of the models were made by using the PyMOL software (PyMOL Molecular Graphics System, version 1.7.4, Schrödinger, LLC, New York).

**In silico splicing prediction**

The intronic mutation found in the PTEN gene (c.1026 +32 T>G) was analyzed in the context of in silico splicing prediction by means of Alamut Visual version 2.9 (Interactive Biosoftware, Rouen, France), which included 5 prediction algorithms (SpliceSiteFinder-like, MaxEntScan, NNSPLICE, GeneSplicer, and Human Splicing Finder). We focused exclusively on the potential impact of the PTEN intronic variant in terms of the disruption of known splice sites or the creation of new potential splice sites.

**CLINICAL REPORT**

**Isolated case**

A 34-year-old female was referred with a chief complaint of a 1-year history of oral lesions. During anamnesis, the patient reported fibrocystic breast disease and an intracystic papilloma in the right breast, multiple benign thyroid nodules, gallbladder calculi, pulmonary centlobular nodules with formation of air cysts, and previously removed epidermoid cysts on her back. Physical examination revealed multiple facial skin papules compatible with trichilemmomas, conjunctival papules, acral keratosis in the palms, and several papules also on the neck and axillae (Figures 1A to 1D). Oral examination revealed the presence of multiple disseminated keratotic papules on the gingiva, alveolar mucosa, and tongue, with the tongue also presenting fissured areas (Figures 1E and 1F). A hyperplastic growth with a papillary surface was also observed in the gingival area close to the right retromolar zone (Figure 1G). The clinical diagnosis was multiple hamartomas associated with CS. The patient complained that the retromolar lesion and 2 other lesions in the anterior upper gingiva made it difficult for her to perform local oral hygiene (inducing sporadic bleeding episodes), and the 3 lesions were surgically removed under cover of local anesthesia. Histologic analysis revealed the presence of an acanthotic, parakeratinized, stratified squamous epithelium with focal papillary areas, and the subjacent connective tissue was permeated by a chronic inflammatory infiltrate and numerous small blood vessels (Figure 1H). The diagnosis was compatible with fibroepithelial inflammatory hyperplasia. The patient was referred for medical evaluation, and surgical removal of some of the skin papules confirmed the diagnosis of trichilemmomas. The patient remains stable and in clinical follow-up for 60 months. No abnormalities were observed in other family members.

Mutational screening revealed c.940 G>T within exon 8 of PTEN, which results in substitution of glutamate (E), at nucleotide position 314, by a stop codon (p.E314*) in the proband (Figure 2A). This substitution was not detected in the proband’s parents. Domain and residue conservation analyses showed that the E314 is highly conserved among mammalian and vertebrate species (Figures 2B and 3C), and 3-D structure analysis revealed that the E314 residue is located in the β7-strand structure of the C2 domain and that the mutation causes the loss of 89 amino acids, resulting in loss of the loop and terminal portion of the domain (Figure 3).

**Familial cases**

A 68-year-old woman (proband) was referred for evaluation of a lump in her tongue; the lump had been increasing in size for the past 2 years. Previous medical history revealed bladder endometriosis, erythema nodosum in the leg, uterine myoma, duodenal ulcer, multiple intestinal polyps, colloid goiter with hyperplastic areas and lymphocytic thyroid, cervical lipoma, cortical renal cysts, and glaucoma. The patient was taking calcium carbonate, levothyroxine, hydrochlorothiazide, and simatriol. Her family history revealed 2 paternal siblings (sister and brother) affected by multiple intestinal polyps and 1 sister by breast cancer and intestinal polyps (Supplementary Figure 1). On physical examination of the proband, multiple cutaneous papules were seen on the face and neck (Figures 4A to 4C), and intraoral examination revealed a nodular lesion of soft, elastic consistency and violet coloration, located at the right lingual apex (Figure 4D). In view of extraoral and intraoral clinical
manifestations, as well as previous medical and family history, the diagnostic hypothesis of CS was considered. The tongue lesion was removed, and the result of the histologic analysis was compatible with intravascular papillary endothelial hyperplasia (Masson’s tumor) (Figures 4E and 4F). The patient is currently under medical and dental follow-up, and no signs of recurrence of the tongue lesion have been observed.

Family members of the proband affected by CS demonstrated an intronic PTEN mutation (c.1026+32 T>G) (Supplementary Figure 2). Asymptomatic members of this family showed a native sequence. In silico analysis of c.1026+32 T>G mutation revealed the creation a new and viable donor splice site, with high predicted scores in all algorithms (SpliceSiteFinder-like, MaxEntScan, and Human Splicing Finder) (Table I).
DISCUSSION

CS is characterized by phenotypic variability, so affected individuals often undergo numerous medical evaluations before a conclusive diagnosis can be made. Although several minimal clinical criteria for definitive diagnosis of CS were proposed, PTEN genetic testing is still required in individuals with typical clinical features. In the current isolated case, the patient demonstrated typical mucocutaneous lesions, including trichilemmomas, palm keratoses, multiple cutaneous facial papules, and oral mucosal papillomatosis, in association with breast, thyroid, and lung lesions, all of which necessitated PTEN genetic analysis. The de novo PTEN mutation c.940 G>T in exon 8, which generates a truncated protein lacking 89 amino acids, was identified. In as many as 45% of cases, CS may be
caused by de novo PTEN mutations, but it has been suggested that many cases of de novo CS, indeed, result from mosaicism in a parent. In the isolated case presented here, the patient’s parents showed no mutations on PTEN, eliminating mosaicism as the cause of her disease. Cases without a family history of CS (de novo CS or mosaicism) make it difficult to arrive at a definitive diagnosis of this condition.

Although lesions in the oral cavity, mainly characterized by oral papillomatosis, are frequently reported in patients with CS, with some authors suggesting that the presence of those features is critical for CS.
diagnosis, in the family case reported here, members of the proband’s family did not show those lesions. Indeed, the diagnosis of CS was only suspected after anamnesis and clinical examination of the proband in association with information regarding various members of family with multiple intestinal polyps and a sister with breast cancer diagnosed at an early age. Development of cancer in multiple organs is frequent in patients with CS, but the most common cancers include female breast, endometrial, thyroid, colon, and renal cancers. Genetic analysis of those family members with clinical phenotypes related to CS revealed a substitution in a critical splicing site region at the exon 8/intron 8 junction, creating a new and viable donor splice site, as predicted by different algorithms. Thus, this study reinforces the importance of family medical history for the diagnosis of CS.

**CONCLUSIONS**

This study found novel mutations in patients with CS, confirming the variable clinical expressivity of signals. Although both mutations have been described in cancer tissues, germline *PTEN* mutations are rare, and additional phenotypic features are almost always

---

**Table 1.** In silico splice site prediction for intronic mutation in *PTEN* (c.1026+32 T>G)

<table>
<thead>
<tr>
<th>Algorithms</th>
<th>Normal sequence</th>
<th>c.1026+32 T&gt;G</th>
</tr>
</thead>
<tbody>
<tr>
<td>SpliceSiteFinder-like [0–100]</td>
<td>0</td>
<td>dss 70.3</td>
</tr>
<tr>
<td>MaxEntScan [0–16]</td>
<td>0</td>
<td>dss 1.2</td>
</tr>
<tr>
<td>NNSPLICE [0–1]</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>GeneSplicer [0–15]</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Human Splicing Finder [0–100]</td>
<td>0</td>
<td>dss 80.1</td>
</tr>
</tbody>
</table>

*c.1026+32 T>G*, T to G transition at position 1026+32 of *PTEN*; dss, donor splice site.
identified in CS cases. Patients with CS should, therefore, be educated about the need for cancer surveillance.

SUPPLEMENTARY MATERIALS
Supplementary material associated with this article can be found in the online version at https://doi.org/10.1016/j.oooo.2018.08.016.

REFERENCES

Reprint requests:
Renato Assis Machado
Department of Oral Diagnosis School of Dentistry
University of Campinas
Piracicaba, São Paulo, Brazil
renatoassismachado@yahoo.com.br